Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
Novo Nordisk has launched NovoCare® Pharmacy, offering all doses of Wegovy® (semaglutide) at a reduced cost of $499 per month for cash-paying patients, with convenient home delivery service. This initiative follows FDA's confirmation that the medicine's shortage is resolved, with supply meeting current and projected U.S. demand.
The program targets uninsured patients or those with commercial insurance lacking obesity medicine coverage. Currently, 90% of Wegovy® patients with coverage pay $0 to $25 monthly. The service includes home shipments through CenterWell Pharmacy, benefit verification, refill reminders, and live support from NovoCare® case managers.
The initiative aims to provide reliable access to authentic, FDA-approved Wegovy® amid concerns about fake or illegitimate compounded semaglutide. Novo Nordisk plans to extend this reduced pricing to cash-paying patients using traditional retail pharmacies in the future.
Novo Nordisk ha lanciato NovoCare® Pharmacy, offrendo tutte le dosi di Wegovy® (semaglutide) a un costo ridotto di $499 al mese per i pazienti che pagano in contante, con un comodo servizio di consegna a domicilio. Questa iniziativa segue la conferma della FDA che la carenza del medicinale è risolta, con l'offerta che soddisfa la domanda attuale e prevista negli Stati Uniti.
Il programma è rivolto a pazienti non assicurati o a quelli con assicurazione commerciale che non copre i farmaci per l'obesità. Attualmente, il 90% dei pazienti che utilizzano Wegovy® con copertura paga tra $0 e $25 al mese. Il servizio include spedizioni a domicilio tramite CenterWell Pharmacy, verifica dei benefici, promemoria per i rinnovi e supporto dal vivo da parte dei case manager di NovoCare®.
L'iniziativa mira a garantire un accesso affidabile a Wegovy® autentico e approvato dalla FDA, in mezzo a preoccupazioni riguardanti semaglutide falsificato o illegittimo. Novo Nordisk prevede di estendere questo prezzo ridotto ai pazienti che pagano in contante utilizzando farmacie al dettaglio tradizionali in futuro.
Novo Nordisk ha lanzado NovoCare® Pharmacy, ofreciendo todas las dosis de Wegovy® (semaglutide) a un costo reducido de $499 por mes para pacientes que pagan en efectivo, con un conveniente servicio de entrega a domicilio. Esta iniciativa sigue la confirmación de la FDA de que la escasez del medicamento se ha resuelto, con el suministro que satisface la demanda actual y proyectada en EE. UU.
El programa está dirigido a pacientes no asegurados o aquellos con seguros comerciales que no cubren medicamentos para la obesidad. Actualmente, el 90% de los pacientes de Wegovy® con cobertura pagan entre $0 y $25 al mes. El servicio incluye envíos a domicilio a través de CenterWell Pharmacy, verificación de beneficios, recordatorios de renovación y soporte en vivo de los gerentes de casos de NovoCare®.
La iniciativa tiene como objetivo proporcionar acceso confiable a Wegovy® auténtico y aprobado por la FDA, en medio de preocupaciones sobre semaglutide falsificado o ilegítimo. Novo Nordisk planea extender este precio reducido a pacientes que pagan en efectivo utilizando farmacias minoristas tradicionales en el futuro.
노보 노르디스크가 노보케어® 약국을 출시하여 모든 용량의 웨고비® (세마글루타이드)를 현금 결제 환자에게 월 $499의 할인된 가격으로 제공하며, 편리한 자택 배송 서비스를 포함합니다. 이 이니셔티브는 FDA가 약물 부족이 해결되었음을 확인한 후, 공급이 현재와 예상되는 미국의 수요를 충족하고 있다는 것을 반영합니다.
이 프로그램은 보험이 없는 환자 또는 비만 치료제 보장이 없는 상업 보험을 가진 환자를 대상으로 합니다. 현재, 웨고비® 환자의 90%가 보험 적용을 받을 경우 월 $0에서 $25를 지불합니다. 이 서비스는 CenterWell Pharmacy를 통한 자택 배송, 혜택 확인, 리필 알림 및 노보케어® 사례 관리자와의 실시간 지원을 포함합니다.
이 이니셔티브는 가짜 또는 불법 조제된 세마글루타이드에 대한 우려 속에서 FDA 승인된 진정한 웨고비®에 대한 신뢰할 수 있는 접근을 제공하는 것을 목표로 합니다. 노보 노르디스크는 향후 전통적인 소매 약국을 이용하는 현금 결제 환자에게도 이 할인 가격을 확대할 계획입니다.
Novo Nordisk a lancé NovoCare® Pharmacy, offrant toutes les doses de Wegovy® (sémaglutide) à un coût réduit de 499 $ par mois pour les patients payant en espèces, avec un service de livraison à domicile pratique. Cette initiative fait suite à la confirmation de la FDA que la pénurie de médicaments est résolue, l'offre répondant à la demande actuelle et prévue aux États-Unis.
Le programme cible les patients non assurés ou ceux ayant une assurance commerciale ne couvrant pas les médicaments contre l'obésité. Actuellement, 90 % des patients sous Wegovy® avec couverture paient entre 0 et 25 $ par mois. Le service comprend des expéditions à domicile via CenterWell Pharmacy, la vérification des avantages, des rappels de renouvellement et un soutien en direct de la part des gestionnaires de cas de NovoCare®.
L'initiative vise à garantir un accès fiable à Wegovy® authentique et approuvé par la FDA, au milieu des préoccupations concernant le sémaglutide falsifié ou illégitime. Novo Nordisk prévoit d'étendre ce prix réduit aux patients payant en espèces utilisant des pharmacies de détail traditionnelles à l'avenir.
Novo Nordisk hat NovoCare® Pharmacy gestartet und bietet alle Dosierungen von Wegovy® (Semaglutid) zu einem reduzierten Preis von 499 $ pro Monat für bar zahlende Patienten an, mit einem bequemen Lieferservice nach Hause. Diese Initiative folgt der Bestätigung der FDA, dass der Arzneimittelengpass behoben ist, wobei das Angebot die aktuelle und prognostizierte Nachfrage in den USA erfüllt.
Das Programm richtet sich an nicht versicherte Patienten oder solche mit einer gewerblichen Versicherung, die keine Deckung für Adipositas-Medikamente haben. Derzeit zahlen 90 % der Wegovy®-Patienten mit Versicherung zwischen 0 und 25 $ pro Monat. Der Service umfasst Hauslieferungen über die CenterWell Pharmacy, Leistungsüberprüfungen, Nachfüllerinnerungen und Live-Support von NovoCare®-Fallmanagern.
Die Initiative zielt darauf ab, einen zuverlässigen Zugang zu echtem, von der FDA genehmigtem Wegovy® zu gewährleisten, angesichts von Bedenken über gefälschte oder illegitime zusammengesetzte Semaglutid-Produkte. Novo Nordisk plant, diesen reduzierten Preis in Zukunft auch für bar zahlende Patienten in traditionellen Einzelhandelsapotheken anzubieten.
- FDA confirms Wegovy shortage is resolved with supply meeting demand
- 90% of insured patients pay only $0-$25 monthly
- 55M+ Americans have coverage for weight management medicines
- Price reduction to $499/month for cash-paying patients
- Future expansion of reduced pricing to retail pharmacies
- Current $499/month price point still relatively high for uninsured patients
Insights
Novo Nordisk's launch of NovoCare Pharmacy marks a significant strategic shift in how the company distributes its blockbuster GLP-1 drug Wegovy. The
Two critical elements make this announcement particularly impactful: First, the FDA has resolved the Wegovy shortage that previously constrained sales growth, with supply now meeting or exceeding both current and projected demand. Second, by establishing a direct distribution channel, Novo Nordisk can better protect brand integrity against counterfeit products while gathering valuable patient data.
While
The timing aligns with expanding insurance coverage, as over 55 million Americans now have specific coverage for weight management medicines. By resolving supply constraints and improving accessibility through multiple channels, Novo Nordisk strengthens its competitive position in the rapidly growing GLP-1 market while potentially accelerating Wegovy revenue growth.
Novo Nordisk's NovoCare Pharmacy represents a significant evolution in pharmaceutical distribution strategy. By establishing direct-to-patient delivery for Wegovy, the company gains several structural advantages: controlled authentic product distribution, direct patient relationships, and reduced reliance on traditional pharmacy networks.
The partnership with CenterWell Pharmacy—a six-time Specialty Pharmacy Patient Choice award winner—brings established capabilities in home delivery infrastructure. This bypasses traditional retail markup while ensuring temperature-controlled handling critical for injectable GLP-1 medications.
The emphasis on "authentic, FDA-approved Wegovy" directly addresses the growing challenge of counterfeit and improperly compounded semaglutide products. This protective measure safeguards both patient safety and Novo Nordisk's brand integrity—particularly important as compounded alternatives have proliferated during previous supply shortages.
Additional services like benefit verification, refill reminders, and dedicated case managers create a more comprehensive patient support ecosystem. This approach potentially improves medication adherence while generating valuable real-world usage data.
The announcement that this pricing will extend to traditional retail channels indicates Novo Nordisk is implementing a hybrid distribution strategy rather than fully disintermediating pharmacies—maintaining important retail relationships while creating competitive pricing pressure across all channels.
- NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of
$499 - While
90% of patients taking Wegovy ® have a co-pay of$0 $25 - Amidst the dangers of fake or illegitimate compounded "semaglutide," NovoCare® Pharmacy offers reliable access to authentic, FDA-approved Wegovy® in our once-weekly, single-dose pen
"Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the
NovoCare® Pharmacy provides cash-paying patients who have been prescribed Wegovy® with the ability to schedule shipments of their Wegovy® prescriptions directly to their home. These home shipments are fulfilled by CenterWell Pharmacy, a six-time Specialty Pharmacy Patient Choice award winner for best-in-class customer satisfaction and commitment to patient care. Beyond convenient home delivery, NovoCare® also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare® case manager. More information about NovoCare® Pharmacy is available at NovoCare.com
Additionally, NovoCare® Pharmacy offers patients access to authentic, FDA-approved Wegovy®, helping to avoid the significant risks that can be posed by the compounding marketplace, as warned by respected organizations, experts in the medical community, and the FDA. With an FDA-approved medicine like Wegovy®, healthcare professionals and patients can have clarity and confidence in knowing the medicine they are using has undergone rigorous review for safety, effectiveness, and quality. In the near future, the overall savings offer for Wegovy® will be updated so that cash-paying patients who use traditional retail pharmacies will also benefit from this lower price.
Novo Nordisk is continuing to take multiple proactive measures to keep patients safe. More information can be found on semaglutide.com.
About Wegovy® (semaglutide) injection 2.4 mg
What is Wegovy®?
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:
- to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use in children under 12 years of age.
Important Safety Information
What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including:
- Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Do not use Wegovy® if:
- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy®
Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:
- have or have had problems with your pancreas or kidneys
- have type 2 diabetes and a history of diabetic retinopathy
- have or have had depression, suicidal thoughts, or mental health issues
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
- are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant
- are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
What are the possible side effects of Wegovy®?
Wegovy® may cause serious side effects, including:
- inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
- gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay colored stools
- increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
- kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration
- severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
- serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy®
- increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
- depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you
- food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy® at https://www.novo-pi.com/wegovy.pdf
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
About CenterWell
CenterWell is a leading health care services business focused on creating integrated and differentiated experiences that put our patients at the center of everything we do. The result is high quality health care that is accessible, comprehensive, and, most of all, personalized. CenterWell is the largest provider of senior-focused primary care, one of the leading providers of home health care, and a leading integrated home delivery, specialty, hospice, and retail pharmacy. CenterWell Pharmacy's home delivery pharmacy services are designed to provide safe, convenient, and affordable access to medications, while supporting adherence to treatment plans.
CenterWell is part of Humana Inc. Learn more about what we offer at CenterWell.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html
SOURCE NOVO NORDISK INC.
FAQ
What is the new monthly cost of Wegovy through NovoCare Pharmacy?
How many patients currently have coverage for Wegovy prescriptions?
Is the Wegovy shortage resolved according to FDA?
Who is eligible for the $499 monthly Wegovy price through NovoCare Pharmacy?
Will the $499 Wegovy price be available at retail pharmacies?
